ReportTwo Year SAVE Outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD
References (5)
- et al.
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
Ophthalmology
(2013) - et al.
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
Ophthalmology
(2013)
Cited by (17)
Nanocarriers: the enhanced potential treatment of age-related macular degeneration
2023, Nanotechnology Principles in Drug Targeting and DiagnosisVisual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials
2021, Ophthalmology RetinaCitation Excerpt :Demographic and clinical information were retrospectively aggregated for subjects entering 12 prospective, investigator-initiated clinical trials within a large, urban retina practice (Retina Consultants of Houston) between 2005 and 2019: Lucentis Utilizing Visudyne (LUV),14 Superdose Anti-VEGF (SAVE),15 Aflibercept for Subjects with Exudative AMD who were Incomplete Responders to Multiple Ranibizumab Anti-VEGF Injections (TURF),16 Rubeosis Anti-VEGF (RAVE),17 RAVE2,18 Wide-Field Angiography Guided Targeted Retinal Photocoagulation Combined with Anti-VEGF Intravitreal Injections for the Treatment of Ischemic Retinal Vein Occlusion (WAVE),19 Treat-and-Extend Age-Related Macular Degeneration (TREX-AMD),20 Efficacy and Safety of Intravitreal Injectinos Combined with Panretinal Photocoagulation for Clinically Significant Macular Edema Secondary to Diabetes Mellitus (DAVE),21 Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination with Intravitreal Aflibercept for the Treatment fo Diabetic Macular Edema (HULK),22 Treat-and-Extend Diabetic Macular Edema (TREX-DME),23 Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy (RECOVERY),24 and Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement (PRIME).25
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up
2020, American Journal of OphthalmologyCitation Excerpt :The current study excluded subjects who did not conduct their study visits at one of the research sites of Retina Consultants of Houston (Houston, Texas, USA). These prospective studies included SAVE,13 DAVE,14 WAVE,15 RAVE,16 TURF,17 ENDURANCE,18 TREX-AMD,19 TREX-DME,20 HULK,21 and RECOVERY.22 Prospective institutional review board (IRB) approval (Sterling IRB, Atlanta, Georgia, USA; Patient Advocacy Council IRB, Mobile, Alabama, USA; Western IRB, Olympia, Washington, USA; Quorum Review IRB, Seattle, Washington, USA) was obtained for all 10 Health Insurance Portability and Accountability Act–compliant study protocols.
Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results
2015, OphthalmologyCitation Excerpt :These are similar proportions to the respective 19% and 34% reported in the Fight Retinal Blindness cohort, which primarily included patients managed with ranibizumab.11 It is unknown whether a different ranibizumab dose5,21–23 or alternative anti-VEGF agents such as aflibercept3 may yield different distributions of extension intervals in a similar patient population. No prior prospective TREX protocol has considered whether an initial maximum extension interval is longitudinally static.
An update on anti-vascular endothelial growth factor therapy in retinal diseases
2023, Chinese Journal of Ocular Fundus DiseasesComparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration
2022, Graefe's Archive for Clinical and Experimental Ophthalmology
Financial Support: Research grant from Genentech. The funding organization had no role in the design or conduct of this research. SAVE Trial: IND 12246, NCT 00406471 http://clinicaltrials.gov/show/NCT00406471.